Factor VIII antibody, Factor VIII [8A] Antibody, Mouse Monoclonal Antibody

Alphabetical Listing of Primary Antibodies:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Alphabetical Listing of Proteins:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Peptides \| Secondary Antibodies \| ELISA Kits

Factor VIII [8A] Antibody, Mouse Monoclonal Antibody

Catalog Number: 20-272-193119

Buy Factor VIII antibody -

Size:

Related Product Names:

- Factor VIII antibody; Factor VIII; 2157; F8; 306700; P00451; AHF; DXS1253E; F8 protein; F8B; F8C; FVIII; HEMA;; Factor VIII [8A]
- Mouse monoclonal [8A] to Factor VIII; 2157; F8; 306700; P00451; AHF; DXS1253E; F8 protein; F8B; F8C; FVIII; HEMA;; Coagulation factor VIII

- Gene Information - Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.

Gene Name: Factor VIII	Gene Name Synonym: 2157; F8; 306700; P00451; AHF; DXS1253E; F8 protein; F8B; F8C; FVIII; HEMA;
Gi #: N/A	NCBI Acc #: NP_000123.1	Swiss Prot Acc #: P00451
Length (aa): N/A	Mol. Weight (Da): 267009	Chrom Location: N/A

Clone: 8A

Isotype: IgG1

Immunogen: Full length native protein (purified) (Human).

Antigen Species: Human

Target: Factor VIII

Concentration: 1 mg/ml

Storage Buffer: Phosphate-buffered saline, pH 7.4, containing no preservatives

Application Note: For ELISA: Use at a diution of 1:16,000. Not tested in other applications. Optimal dilutions/concentrations should be determined by the researcher.

Myeloma: NS1

Source/Host: Mouse

Purity/Purification: Protein G purified

Clonality: Monoclonal

Crossreactivity: Human - Not yet tested in other species

Format: Liquid

Storage: Keep as concentrated solution. Store at 4C short term. For extended storage aliquot and store at -20C or below. Avoid freeze-thaw cycles.

Shipping: Products may be shipped on ice pack or dry ice.

APPLICATIONS for FACTOR VIII ANTIBODY:

ELISA: Tested

TESTING: (secondary reagents and protocols )

Not Available

FACTOR VIII ANTIBODY TARGET DESCRIPTION:

Synonym Names for Factor VIII antibody: Factor VIII; 2157; F8; 306700; P00451; AHF; DXS1253E; F8 protein; F8B; F8C; FVIII; HEMA;; Mouse monoclonal [8A] to Factor VIII; 2157; F8; 306700; P00451; AHF; DXS1253E; F8 protein; F8B; F8C; FVIII; HEMA;; Coagulation factor VIII

Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal; they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients; F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is nonfunctional; i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.

Function: Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.

Subunit: Interacts with vWF. vWF binding is essential for the stabilization of F8 in circulation.

Subcellular Location: Secreted, extracellular space.

Domain: Domain F5/8 type C 2 is responsible for phospholipid-binding and essential for factor VIII activity.

Ptm: Sulfation on Tyr-1699 is essential for binding vWF.

Mass Spectrometry: Mass=1367.6; Method=Electrospray; Range=356-378; Note=Nonsulfated; Source=PubMed:10368977;.

Mass Spectrometry: Mass=1407.4; Method=Electrospray; Range=356-378; Note=Sulfated; Source=PubMed:10368977;.

Mass Spectrometry: Mass=2975.4; Method=Electrospray; Range=400-424; Note=Nonsulfated; Source=PubMed:10368977;.

Mass Spectrometry: Mass=3024; Method=Electrospray; Range=727-752; Note=Nonsulfated; Source=PubMed:10368977;.

Mass Spectrometry: Mass=3104; Method=Electrospray; Range=727-752; Note=Monosulfated; Source=PubMed:10368977;.

Mass Spectrometry: Mass=3183.5; Method=Electrospray; Range=727-752; Note=Disulfated; Source=PubMed:10368977;.

Mass Spectrometry: Mass=3262.5; Method=Electrospray; Range=727-752; Note=Trisulfated; Source=PubMed:10368977;.

Mass Spectrometry: Mass=2460.9; Method=Electrospray; Range=1672-1692; Note=Nonsulfated; Source=PubMed:10368977;.

Mass Spectrometry: Mass=2540.7; Method=Electrospray; Range=1672-1692; Note=Sulfated; Source=PubMed:10368977;.

Mass Spectrometry: Mass=2000.7; Method=Electrospray; Range=1691-1708; Note=Nonsulfated; Source=PubMed:10368977;.

Mass Spectrometry: Mass=2080.7; Method=Electrospray; Range=1691-1708; Note=Sulfated; Source=PubMed:10368977;.

Disease: Defects in F8 are the cause of hemophilia A (HEMA) [MIM:306700]. HEMA is a common recessive X-linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal; they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients; F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is non-functional; i.e., the F8C activity is much less than the plasma protein level. CRM-reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.

Pharmaceutical: Available under the names Kogenate (Bayer) and Recombinate (Baxter and American Home Products). Used to treat hemophilia A.

Similarity: Belongs to the multicopper oxidase family.

Similarity: Contains 3 F5/8 type A domains.

Similarity: Contains 2 F5/8 type C domains.

Similarity: Contains 6 plastocyanin-like domains.

Factor VIII [8A] reacts with human - not yet tested in other species.

OMIM: 134500; phenotype. [NCBI / EBI]
306700; gene+phenotype. [NCBI / EBI]

Products similar to Factor VIII antibody:

IgG

VWF, IgG

ZNF84 (zinc finger protein 84), IgG

MPPED2 (metallophosphoesterase domain containing 2), IgG

CD30, IgG

zinc finger E-box binding homeobox 1 (ZEB1), IgG

Native_Protein

Von Willebrand Factor Ag, Native_Protein

Factor VIII RA Human, Protein

Myostatin Human, His, Protein

Myostatin Human, Protein

Factor-VIII Human, Protein

SUGGESTED ANITBODY REAGENTS - GenWay has an extensive selection of reagents useful for antibody applications. Find blocking buffers, stop reagents, chemiluminescent substrates, diluents, Immunohistochemistry reagents & more.

Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.

Precautions: Factor VIII antibody is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.

Important Notes: During shipment, small volumes of Factor VIII antibody vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.

Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about Factor VIII antibody, all related information, articles, resources about Factor VIII antibody are being stored on our online database. Let us know if you have questions regarding this product.

Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed.

GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.

Thank you for visiting GenWay Biotech's Datasheet. GenWay is the world's leader in chicken, IgY antibody production, producing over 900 quality polyclonal IgY antibodies to date. From our unique recombinant protein production, utilizing a variety of protein expression systems, GenWay's polyclonal IgY antibodies incorporate more epitopes, increasing the success rate for ELISA, western blot, immunohistochemistry (IHC), immunocytochemistry (ICC), and many more immunoassays.



GenWay Biotech, Inc. 6777 Nancy Ridge Drive, San Diego, CA 92121 Tel: (858)458-0866 Fax: (858)458-0833 Email: sales@genwaybio.com www.genwaybio.com ©1998 - 2010 GenWay Biotech, Inc. - All Rights Reserved